Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-23
    E.g., 2018-09-23

Articles

173342 items
12:16 PM, Sep 14, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Hua raises $110.5M in HK IPO, trades flat on first day

Hua Medicine Ltd. (HKSE:2552) shares ended the day unchanged at HK$8.28 in the company's first day of trading Sept. 14. The diabetes play raised HK$867 million ($110.5 million) in an IPO through the sale of...
12:16 PM, Sep 14, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Atreca’s $125M round paves way for first immunotherapy into clinic

Atreca Inc. (Redwood City, Calif.) raised $125 million in a series C round led by an undisclosed U.S.-based healthcare fund, clearing the way for the company to move its first cancer immunotherapy into the clinic. Fellow...
12:16 PM, Sep 14, 2018  |  BC Week In Review | Company News  |  Sales & Marketing

MS Society protests NICE rejection of Ocrevus for primary progressive MS

The U.K.'s NICE issued a final appraisal determination (FAD) on Sept. 10 recommending against the use of Ocrevus ocrelizumab from Roche (SIX:ROG; OTCQX:RHHBY) to treat primary progressive multiple sclerosis with imaging features characteristic of inflammatory...
12:16 PM, Sep 14, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Filgotinib meets in Phase III FINCH 2 study for RA

Gilead Sciences Inc. (NASDAQ:GILD) and Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) said both doses of filgotinib met the primary and all key secondary endpoints in the Phase III FINCH 2 trial to treat rheumatoid arthritis. Filgotinib is...
12:15 PM, Sep 14, 2018  |  BC Week In Review | Company News  |  Deals

Oncolytics to conduct pilot study of oncolytic virus with SOLTI

Oncolytics Biotech Inc. (TSX:ONC; NASDAQ:ONCY) partnered with the non-profit group SOLTI (Barcelona, Spain) to conduct a pilot study of the biotech's Reolysin pelareorep in the neoadjuvant setting for breast cancer. SOLTI will facilitate the trial,...
12:15 PM, Sep 14, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Novocure planning submission for TTFields in mesothelioma

Novocure Ltd. (NASDAQ:NVCR) reported final data from the Phase II STELLAR trial to treat previously untreated unresectable malignant pleural mesothelioma showing that its Tumor Treating Fields (TTFields) plus standard of care (SOC) chemotherapy significantly improved...
10:29 AM, Sep 14, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Xenon further strengthens balance sheet with $63M follow-on

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) raised $63 million through the sale of 4.5 million shares at $14 in a follow-on underwritten by Jefferies and Stifel. The price is a 2% discount to Xenon's closing price of $14.25...
10:29 AM, Sep 14, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Neurological organoid company System1 raises $25M in series A

System1 Biosciences Inc. (San Francisco, Calif.) raised $25 million in a series A round co-led by CRV and Pfizer Ventures. Alexandria Venture Investments, Dolby Family Ventures, Longevity Fund, Riot Ventures, Kinled Holding, Wilmot Ventures, Webb...
10:29 AM, Sep 14, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Epic raises $52M series E

Epic Sciences Inc. (San Diego, Calif.) raised $52 million in a series E round led by Blue Ox Healthcare Partners. Fellow new investors Deerfield Management and Varian Medical Systems Inc. (NYSE:VAR) joined existing investors Altos...
10:28 AM, Sep 14, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

MPM, Versant launch gene therapy play Coda

Coda Biotherapeutics Inc. (South San Francisco, Calif.) debuted with a $19 million series A round led by seed investors MPM Capital and Versant Ventures. New investors Astellas Venture Management and Novartis AG (NYSE:NVS; SIX:NOVN) also...

Pages